Overview

Update
Total Equity Funding
$9.43M in 2 Rounds from 5 Investors
Most Recent Funding
$6.4M Series B on September 17, 2014
Headquarters:
Snodland
Description:
MGB Biopharma develops DNA minor groove binders-based anti-infective medicines.
Categories:
Medical Device, Health Care, Biotechnology
Website:
http://www.mgb-biopharma.com
Social:

Company Details

Update

MGB Biopharma Limited is a biopharmaceutical company established to develop a completely new class of anti-infective medicines based upon compounds which are DNA Minor Groove Binders (MGB)

The company has an exceptionally experienced team from both pharma and biotech sectors and is dedicating its focus initially to the development of small molecules with specific antibacterial efffects against resistant bacteria

By selecting a new class of antibacterial, the company believes the novel mode of action should prove to be very potent against bacteria as these target organisms will lack any inherent resistance, unlike that typically facing new drugs which are the result of modifications from existing classes of drugs used to treat bacterial infection

Funding Rounds (3) - $11.61M

Update
DateAmount / RoundValuationLead InvestorInvestors
Sep, 2014$6.4M / Series B4
Jun, 2014£1.3M / Grant1
Mar, 2010$3.03M / Series A4

Current Team (3)

Update

Board Members and Advisors (3)

Update

Offices/Locations (1)

Update
  • Office

    151 West George Street

    Glasgow

    Snodland, G2 2JJ

    GBR

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos